Abstract
Patients with higher-risk myelodysplastic syndromes (HR-MDS), if left untreated have lower overall survival and increased economic burden. This systematic literature review (SLR) identified comprehensive evidence on the economic burden of disease among patients with low-to-high risk MDS. Methodology: Literature search of English publications from 2011-2021 was conducted in Embase®, MEDLINE® and MEDLINE-In-process, including relevant conference proceedings to identify economic burden of MDS that fulfilled pre-defined inclusion criteria.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
